Inhibitor Therapeutics INTI
OTC INTI
$0.11 +0.00 (+0.00%)
At close: Oct 19, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Notes Payables (2013 - 2022)

Updated

Inhibitor Therapeutics' Notes Payables came in at $411,000 for Q4 2022, up 77.9% from $231,000 a year earlier and unchanged from the prior quarter.

Analysis

Inhibitor Therapeutics (INTI) Notes Payables (2013 - 2022) Analysis & Trends

Going back to Q3 2013, Inhibitor Therapeutics' Notes Payables data covers 13 quarters.

  • Going back by year, Notes Payables was $231,000 in FY2021 (+668.9%) and $30,044 in FY2020.
  • Business Quant data shows INTI's Notes Payables at $411,000 (Q3 2022), $331,000 (Q2 2022) and $281,000 (Q1 2022) in the three quarters before Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Inhibitor Therapeutics 19.12 Mn 11.93 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 411,000.00
Sep 30, 2022 411,000.00
Jun 30, 2022 331,000.00
Mar 31, 2022 281,000.00
Dec 31, 2021 231,000.00
Dec 31, 2020 30,044.00
Sep 30, 2020 23,111.00
Jun 30, 2020 16,178.00
Sep 30, 2014 41,920.00
Jun 30, 2014 102,420.00
Mar 31, 2014 77,701.00
Dec 31, 2013 68,428.00
Sep 30, 2013 68,428.00
API Access

Inhibitor Therapeutics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=INTI&period=max&api_key=YOUR_API_KEY